FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
Sept 23 (Reuters) - Scholar Rock Holding Corp SRRK.O:
FDA ISSUES COMPLETE RESPONSE LETTER (CRL) FOR APITEGROMAB AS A TREATMENT FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA) SOLELY RELATED TO OBSERVATIONS IDENTIFIED AT CATALENT INDIANA LLC FILL-FINISH FACILITY
SCHOLAR ROCK HOLDING CORP - NO OTHER APPROVABILITY ISSUES CITED IN CRL
SCHOLAR ROCK HOLDING CORP - INTENDS TO RESUBMIT APITEGROMAB BLA AFTER CATALENT ISSUES
SCHOLAR ROCK: OUTSIDE U.S., APITEGROMAB MAA UNDER REVIEW BY EMA, DECISION EXPECTED NEAR MID-2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Navitas Stock’s AI Data Center Pivot: Up 88% YTD—Is NVTS Stock Still a Buy?

Tradingkey







